According to the Changchun Hi-Tech announcement, Jinsaizeng, independently developed by its holding subsidiary Jinsai Pharmaceutical, and Meishiya, which was cooperatively introduced, have all been newly included in the “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue”. The standard medical insurance payment period is valid from January 1, 2026 to December 31, 2027. This inclusion reflects the country's recognition of relevant drugs, which is conducive to marketing and increasing sales scale. The impact on the company's performance cannot yet be estimated. The new version of the catalogue will be implemented on January 1, 2026, and the reimbursement rules are subject to government announcements.

According to the Changchun Hi-Tech announcement, Jinsaizeng, independently developed by its holding subsidiary Jinsai Pharmaceutical, and Meishiya, which was cooperatively introduced, have all been newly included in the “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue”. The standard medical insurance payment period is valid from January 1, 2026 to December 31, 2027. This inclusion reflects the country's recognition of relevant drugs, which is conducive to marketing and increasing sales scale. The impact on the company's performance cannot yet be estimated. The new version of the catalogue will be implemented on January 1, 2026, and the reimbursement rules are subject to government announcements.